We would like to thank Cox and colleagues for their comments on our article (1). They assert that the only demonstration of value of MRI screening is in genetically high-risk populations, who develop early, aggressive cancers, presumably referring to patients with BRCA1/2 mutations. However, the American Cancer Society guidelines recommend MRI screening for women with a risk of greater than 20% based on family history, a much broader population than just BRCA1/2 mutation carriers. The intent of our study was to investigate the potential for using single-nucleotide polymorphism (SNP) data to refine estimates of risk for women who are not BRCA1/2 carriers but who are at intermediate to high risk based on the Gail test.

Cox and colleagues also state that MRI screening has been shown to have little benefit after the age of 60 years. This is in part due to the fact...

You do not currently have access to this content.